WO1998015830A2 - Homogenous luminescence energy transfer assays - Google Patents
Homogenous luminescence energy transfer assays Download PDFInfo
- Publication number
- WO1998015830A2 WO1998015830A2 PCT/FI1997/000560 FI9700560W WO9815830A2 WO 1998015830 A2 WO1998015830 A2 WO 1998015830A2 FI 9700560 W FI9700560 W FI 9700560W WO 9815830 A2 WO9815830 A2 WO 9815830A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- acceptor
- donor
- energy transfer
- assay
- label
- Prior art date
Links
- XDTMQSROBMDMFD-UHFFFAOYSA-N C1CCCCC1 Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/64—Fluorescence; Phosphorescence
- G01N21/6408—Fluorescence; Phosphorescence with measurement of decay time, time resolved fluorescence
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6816—Hybridisation assays characterised by the detection means
- C12Q1/6818—Hybridisation assays characterised by the detection means involving interaction of two or more labels, e.g. resonant energy transfer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/64—Fluorescence; Phosphorescence
- G01N21/6428—Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes"
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
- G01N33/542—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57434—Specifically defined cancers of prostate
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6869—Interleukin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
- G01N33/743—Steroid hormones
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
- G01N33/76—Human chorionic gonadotropin including luteinising hormone, follicle stimulating hormone, thyroid stimulating hormone or their receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/64—Fluorescence; Phosphorescence
- G01N21/6428—Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes"
- G01N2021/6439—Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes" with indicators, stains, dyes, tags, labels, marks
- G01N2021/6441—Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes" with indicators, stains, dyes, tags, labels, marks with two or more labels
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2458/00—Labels used in chemical analysis of biological material
- G01N2458/40—Rare earth chelates
Definitions
- the present invention relates to improvements of energy- transfer based homogeneous assays, which use time-resolved fluorometry in detection.
- the specific improvements relate to the type of lanthanide chelate labels used as energy donors, optimized energy acceptors for defined assays, the way energy transfer is measured using optimized filters and time windows, ways to correct all possible interferences derived from samples, use the assay for multi-component analysis and development of simplified assay protocols.
- assays based on bioaffinity or enzymatically catalysed reactions have been developed to analyze biologically important compounds from various biological samples (such as serum, blood, plasma, saliva, urine, feces , seminal plasma, sweat, liquor, amniotic fluid, tissue homogenate, ascites, etc.), samples in environmental studies (waste water, soil samples) industrial processes (process solutions, products) and compound libraries (screening libraries which may comprise organic compounds, inorganic compounds, natural products, extracts of biological sources, biological proteins, peptides, or nucleotides, and so on).
- biological samples such as serum, blood, plasma, saliva, urine, feces , seminal plasma, sweat, liquor, amniotic fluid, tissue homogenate, ascites, etc.
- samples in environmental studies waste water, soil samples
- industrial processes process solutions, products
- compound libraries screening libraries which may comprise organic compounds, inorganic compounds, natural products, extracts of biological sources, biological proteins, peptides, or nucleotides,
- Some of these assays rely on specific bioaffinity recognition reactions, where generally natural biological binding components are used to form the specific binding assay (with biological binding components such as antibodies, natural hormone binding proteins, lectins , enzymes, receptors, DNA, RNA or PNA) or artificially produced binding compounds like genetically or chemically engineered antibodies, molded plastic imprint (molecular imprinting) and so on.
- Such assays generally rely on a label to quantitate the formed complexes after recognition and binding reaction and suitable separation (separations like precipitation and centrifugation, filtration, affinity collection to e.g. plastic surfaces such as coated assay tubes, slides of microbeads, solvent extraction, gel filtration or other chromatographic systems, and so on).
- the quantitation of the label in free or bound fraction enables the calculation of the analyte in the sample directly or indirectly, generally through use of a set of standards to which unknown samples are compared.
- Time-resolved fluorometry (time resolution in time-domain at micro- or millisecond range) is a perfect measuring regime for homogeneous assays, because it can totally discriminate the background fluorescence derived from organic compounds when long enough delay times (time between pulsed excitation and starting of emission recording) are used (for a review see. e.g. Hemmila (1991); Gudgin Dickinson et al, (1995) J Photochem Photobiol 27, 3).
- delay times time between pulsed excitation and starting of emission recording
- the aim of the present invention is i.a. to provide an improvement in time- resolved homogeneous assay principle based on specific energy transfer between a long life-time chelate-based donor probe and short life-time (or non-emitting) acceptor molecule.
- r is the distance between the donor and acceptor molecules and R 0 is a distance parameter characteristic of the donor-acceptor pair and the medium between them.
- Fluorescence resonance energy transfer has been applied e.g. as an spectroscopic ruler in structural studies to measure distances within a macromolecule (Stryer and Haugland (1967) Proc Natl Acad Sci, USA, 58; 719).
- resonance energy transfer there are also other energy transfer reactions, like simple radiative (where acceptor absorbs the light emitted by donor), collisional energy transfer, exchange (Dexter (1953) J Chem Physics, 21, 836) and exciton migration (in crystals).
- the donor emission can be quenched by numerous ways with a number of unrelated compounds having an deactivating effect on some of the donor's energy levels.
- FETIA primarily applies xanthene dyes and derivatives of fluorescein as donor and rhodamines as acceptors .
- a great number of alternative probe pairs have since been developed and applied in immunoassays (for a review see Hemmila 1991, chapter 8.3.4) including practically non-fluorescent derivatives of fluorescein, long life-time delayed fluorescence emittive eosin (Thakrar and Miller (1982) Anal Proc, 19, 329), long lifetime fluorescent pyrene (Morrison (1988) Anal Biochem, 174, 101) and non-e ittive charcoal.
- FRET has since got wide applications in basic research and in DNA hybridizations (see e.g. Morrison et al (1989) Anal Biochem, 183, 231; Parkhurst et al (1995) Biochemistry, 34, 285) and other assays were association, dissociation or distances are to be measured.
- temporal discrimination time-resolution
- organic donor-acceptor pairs of different decay times using pyrene as the long excited state donor, pulsed laser for excitation and phycoerythrin as the short decay-time acceptor (US 4,822,733).
- time-resolved energy transfer principle is applied for homogeneous solution hybridization using fluorescein (Morrison et al (1989) Illrd International Symposium on Quantitative Luminescence Spectrometry in Biomedical Sciences, Ghent Belgium) as acceptor.
- the long excited state provides the advantage, that specific energy transfer can be followed using a delay time, during which the emission of directly excited acceptor is decayed off.
- the combination of different decay times exploited in time- resolved fluorometry will provide a clear advantage over FRET technologies employing conventional short decay probes .
- Luminescent (fluorescent) lanthanides have long been used as tools for DNA and protein structural studies (See e.g. Brittain (1985) Bioinorganic Luminescence Spectroscopy, Schulman (ed), Molecular Luminescence Spectroscopy, Wiley, NY; B ⁇ nzli and Choppin (1989) Lanthanide Probes in Life, Chemical and Earth Sciences, Theory and Practice, Elsevier Science Publisher, Amsterdam), applied e.g. for RNA, ribosomes, DNA and chromatin, termolysin and transferrin, calmodulin, ATPase, nerve membranes, erythrocyte membrane proteins, phospholipids and liposomes and their fusions (for an review see Hemmila 1991).
- Lanthanides and their chelates are good candidates for time-resolved FRET experiments. Firstly, they have exceptionally long excited state lifetime (Weissman (1942) Chem Phys, 10, 214; Whan and Crosby (1962) Mol Spectrosc, 8, 315). The energy transfer takes place only between transitions that are electric dipole. The major transition in the highly fluorescent Eu chelates, (transition D 0 - 7 F 2 ) at 612-620 n is electric dipole "forced" (B ⁇ nzli (1989) Lanthanide Probes in Life, Chemical and Earth Sciences. Theory and Practice, B ⁇ nzli and Choppin (ed) Elsevier Science, Publisher, Amsterdam) and can donate energy.
- transition D 0 - F x producing emission at 590-595 nm is, however, magnetic dipole and can not transfer energy (Dexter, J Chem Phys 21? 836, 1953).
- lanthanide emission has isotropic dipolic moment, and hence the orientation factor becomes less ambiguous (Ando et al
- Fluorescent lanthanide chelates have been used as energy donors already since 1978 by Stryer, Thomas and Meares.
- a Tb dipicolinate chelate reported to have the critical distance (R 0 ) of 6.57 nm for rhodamine, 4.46 nm for eosin and 4.46 nm for NBD (Thomas et al (1978) Proc Natl Acad Sci, 75; 5746).
- R 0 critical distance
- the overall decay shortens, as shown in the above system, from 2.22 ms to 0.12 ms .
- the preferred chelate is composed of nona-dentate chelating ligand, such as terpyridine (EP-A 403593; US 5,324,825; US 5,202,423, US 5,316,909), terpyridine analogue with one or two five-membered rings (e.g. pyrazole, thiazole, triazine) (US Appl 08/548,174 and PCT/FI91/00373) .
- terpyridine EP-A 403593; US 5,324,825; US 5,202,423, US 5,316,909
- terpyridine analogue with one or two five-membered rings e.g. pyrazole, thiazole, triazine
- Very well suited chelates are also mentioned in following articles (Takalo et al (1994)
- Hoffman La Roche has patented a specific application using lumazine-t pe of chromophore as donor and a ruthenium chelate as acceptor for interactions between nucleic acids (EP 439036) and Cis Bio International applied for an assays based on Eu or Tb cryptates as donors for phycobiliproteins (WO 92/01225) .
- the principle of a time-resolved homogeneous assay based on a specific energy transfer between a long-life time donor and a short life-time emitting acceptor molecule can be summarized as follows:
- the emission duration of a short excited state acceptor, excited during the excited lifetime of a long-decay time donor through the mechanism of energy transfer, is longer than the decay time of the directly excited acceptor. This fact permits the use of temporal discrimination (time-resolution) to avoid the luminescence from directly excited acceptor.
- A light pulse
- the luminescence emission of the energy-transfer excited acceptor is measured (D) after a suitable delay (C), to avoid interference derived from directly excited acceptor (B).
- the long-lived emission from the donor (DE) is avoided by measuring the emission of the energy-transfer excited acceptor (AE) at a wavelength where the donor emission is absent or negligible ( Figure 2).
- AE emission of the energy-transfer excited acceptor
- An object of the present invention is to provide a luminescence energy transfer assay comprising a first group labelled with an energy donor and a second group labelled with an energy acceptor, wherein the acceptor is either a short excited state lifetime luminescent label or a non- luminescent label.
- the donor is a luminescent lanthanide chelate.
- the assay is based on a reaction resulting in lengthening of the distance between the labelled donor and acceptor groups .
- the donor luminescent lanthanide chelate has a long excited state lifetime.
- the assay is based on a reaction resulting in either shortening or lengthening of the distance between the labelled donor and acceptor groups and the donor is a luminescent lanthanide chelate having a long excited state lifetime.
- the long excited state lifetime luminescent lanthanide chelate has one or more of the following properties:
- two or more analytes are simultaneously measured, wherein each analyte is measured by a specific donor-acceptor pair.
- the luminescent or non-luminescent label of the acceptor is attached to a solid carrier providing a large surface to which said second group is bound or can be bound via suitable covalent or non-covalent means.
- the acceptor is lipophilic compound anchored to a cell membrane or cell membrane fragment or the acceptor is made lipophilic by conjugating with a long chain hydrocarbon such as a fatty acid.
- the instrument used to measure energy transfer is able to follow multiple parameters simultaneously or consecutely, such as absorbances at the wavelenghts of excitation or emissions, luminescence of different durations, scattering and luminescence decay times, in order to monitor and correct any interferences the sample matrix may have to excitation, energy transfer or emissions.
- Figure 1 shows the luminescence versus time after donor excitation with a light pulse (A) of directly excited acceptor (B) and the luminescence emission of the energy- transfer excited acceptor (D) after a suitable delay (C).
- Figure 2 shows the luminescence intensity versus emission wavelength of donor (DE) and acceptor (AE).
- Figure 3 shows a standard curve for the homogenous energy transfer assay of BhCG ( ⁇ -subunit of human chorionic gonadotropin) .
- Figure 4 shows a standard curve for the homogenous energy transfer assay of PSA (prostate specific antigen).
- Figure 5 shows a standard curve for the homogenous energy transfer assay of ⁇ hCG using indirect labelling.
- Figure 6 shows a standard curve for the homogenous energy transfer assay of ⁇ hCG using indirect labelling and an acceptor different from that of Figure 5.
- the present invention relates to improvements of energy- transfer based homogeneous assays, which use time-resolved fluorometry in detection.
- the specific improvements relate to the type of lanthanide chelate labels used as energy donors, optimized energy acceptors for defined assays, the way energy transfer is measured using optimized filters and time windows, ways to correct all possible interferences derived from samples, use the assay for multi-component analysis and development of simplified assay protocols.
- first group and second group shall be understood to include any component such as bioaffinity recognition component (in reactions where the distance between the groups decreases, e.g. in bioaffinity reactions) or a part of a molecule or substrate (e.g. the distal ends of a peptide molecule the cleavage of which will separate the two labelled groups from each other).
- bioaffinity recognition component in reactions where the distance between the groups decreases, e.g. in bioaffinity reactions
- substrate e.g. the distal ends of a peptide molecule the cleavage of which will separate the two labelled groups from each other.
- luminescence shall cover fluorescense, phosphorescence, chemiluminescence, bioluminescence and electro-generated luminescence, photoluminescence, radioluminescence, sonoluminescence, thermoluminescence and triboluminescence .
- a preferred arrangement in assays, where association is to be measured is to use luminescent, short decay time acceptor and long decay time lanthanide chelate based donor and follow the emission of acceptor molecule using a delay time in the time-resolved fluorometry to avoid the interference of acceptors direct luminescence (emanating from direct excitation of acceptor). It is desirable to construct the assay in a way that acceptor molecules are in excess (with time-resolved mode, their interference is negligible) and the association of binding reagents creates an increase in signal.
- the preferred chelate label has to have high luminescence yield ( Ex ⁇ >2000), long excited state lifetime (preferably over 1 ms ) and emission distribution optimized for energy transfer.
- the ligand field around the chelated ion has to be such that e.g. with Eu chelates over 70 % of emission is at D 0 - F 2 (at 610 - 620 nm range) and not at 590 nm range (compare e.g. emissions of Eu cryptate, WO 92/01225 and those of bis-iminoacetate derivatives of terpyridines, US 5,324,825; US 5,202,423 and US 5,316,909).
- chelates In preferred chelates the useless magnetic dipole transition at 590 nm and emission around 700 nm are suppressed (Li and Selvin, J Amer Chem Soc 117; 8132, 1995).
- Particularly good chelates for the present application are Eu chelates formed with multichromogenic polycarboxylates, having high molar absorption coefficient (G), very long excited state lifetime and good quantum yield ( ⁇ ) (Takalo et al . Helv Chim Acta 79; 789, 1996).
- G molar absorption coefficient
- ⁇ quantum yield
- Tb is particularly promising energy donor, when its highly luminescent chelates are used.
- a preferred Tb chelate is composed of terpyridine derivatives containing the binding side at the iminodiacetate group (Mukkala et al, J Alloys Compounds 225; 507, 1995) or otherwise a binding arm well isolated from the light absorbing aromatic structure.
- Particularly good chelates for that applications are terpyridine derivatives where one or two pyridine rings are replaced with pyrazole (US 08/548,174) or triazole and thiazole rings (PCT/FI91/00373 ) .
- the use of S would give the possibility to make double- or triple-label homogeneous energy transfer assays.
- Sm has the advantage, that it can donate energy at a rather high wavelength, the major emission of a highly luminescent chelate being at 643 nm, giving the opportunity to continue with the wavelength scale up to near IR (a good collection of near-IR emitting fluors have become commercially available from different sources).
- a preferred stable chelate of Sm is composed of multiple forms of 1 , 3-diketones , such as described by Savitsky (Savitsky et al, SPIE 2388; 429, 1995).
- An alternative third choice (third label) is the phosphorescent Pt or Pd coproporphyrins emitting a long lifetime phosphorescence at 650-660 nm (WO 94/10568) .
- a particularly preferred group of long excited state lifetime lanthanide chelates are Compounds 1 to 12 the structure of which is dislosed in Scheme 1 to 5.
- ⁇ exc means excitation wavelength, ⁇ decay time and G x ⁇ luminescence yield.
- the values given in the schemes are measured from the compound coupled to a protein. 98/15830
- a preferred acceptor molecule for association assay is highly luminescent (with quantum yield as near unity (1) as possible) with high molar absorption coefficient (preferably over 100 000).
- the absorption of the acceptor has to overlap with the energy-donating emission of donor, i.e. at 611-620 nm for Eu, 545 nm for Tb, 643 nm for Sm.
- a preferred feature of the acceptor is its sharp emission at a wavelength where donor does not have any emission (such as 574-575 nm for Tb, 660-670 nm for Eu and around 675 for Sm) .
- the decay-time of the acceptor should be below l ⁇ s .
- the acceptor has to be attached to binding partners, either directly or indirectly (e.g.
- covalently conjugated probes e.g. those of xanthene dyes (rhodamine, tetramethylrhodamine, Texas
- a good acceptor for Eu should have absorption maximum at 611-620 nm range. Good acceptor for that wavelength range can be found particularly from the group of IR emittive dyes (for reviews see Haugland Molecular Probes, Miller, Spectroscopy Europe 5; 34, 1993, Patonay and Antoine, Anal Chem 63; 332A, 1991, Southwick et al, Cytometry 11; 418, 1990, Mujumbar et al, Cytometry 10; 11, 1989 and Mujumbar et al, Bioconjugate Chem 4; 105, 1993, Papkovsky, Appl Fluorescence Technol III; 16, 1991, Schindele and Renzoni, J Clin Immunoassay 13; 182, 1993).
- phthalocyanines phthalocyanines
- porphyrins cyanine dyes
- cyanine dyes Cy-5, Cy5,18, Cy5,29
- rhodamine 800 conjugated xanthenes
- squarates Chang, EP176,252
- methylene blue, Nile blue and oxazines Imasaka et al, Anal Chem 61; 2285, 1989
- indocyanine green Imasaka et al, Anal Chem 62; 363A, 990.
- phycobiliproteins are good candidates also for Eu acceptors, particularly A- PC, C-PC and R-PC .
- a preferred energy acceptor for Sm or for coproporphyrins are the IR emittive dyes (see reviews mentioned above).
- a preferred way to ascertain small distances between donor probe labelled ligand or binding reagent and acceptor probe labelled binding reagent is to use activated probes coupled directly to binding reagent (e.g. acceptor labelled receptor protein, antibody or other binding protein).
- binding reagent e.g. acceptor labelled receptor protein, antibody or other binding protein.
- An alternative way is to use indirect labelling, using e.g. anti-binder (such as anti-receptor) antibodies labelled with the acceptor, use of biotinylated binder and acceptor labelled ( strept )avidin or to employ other bioaffinity reactions to bring acceptor molecules in the vicinity of actual binding site, where the donor-labelled component either directly or indirectly will be bound.
- a preferred way with impure, membrane-bound receptors is to use lipophilic membrane probes and stain all the membranes near or around the receptor with acceptor molecules .
- Suitable probes attached to long aliphatic hydrocarbon chain such as e.g. oxacarbocyanine (Molecular Probes) are suitable for such staining.
- Suitable solid carriers can be e.g. beads or particles with a diameter up to 1500 ⁇ m or any solid surface.
- Microbeads labelled with a wide variety of luminescent probes are available from different sources.
- a preferred probe used in the carrier is a hydrophobic compound, having negligible solubility to water to avoid leakage.
- a variety of probes suitable for such labelling can be found amongst scintillator and laser dyes .
- the great number of acceptor molecules may compensate the long distance after bead coating, and the luminescent bead actually provide a energy accepting surface.
- the bead can absorb most of the donor emitted light, a simple radiative enery transfer can be applied, in which the energy transfer is a function of space angle and critical distance with 10 ⁇ m beads is in the range of micrometers.
- the binding proteins e.g. agglutinin
- a preferred arrangement is thus to use surface activated beads and use part of the reactive groups for coupling with acceptor molecules, or use acceptor-labelled binding surface (such as rhodamine labelled agglutinin) or to label coated protein afterwards with acceptors .
- the preferred way to measure binding is to follow acceptor signal increase.
- the acceptor signal is measured using a filter optimized for the donor used, having good transmission at the wavelength of acceptor, but more importantly, absolutely well blocked for each emission lines of the donor.
- the filter should not leak any emission emanating form the main emission line of donor (such as 545 or 490 nm of Tb and 613-615 nm of Eu).
- the energy transfer filter has to be situated at wavelength area, where there are no minor emission lines with the used donor.
- Use of suitable delay avoid the interference derived from direct excitation of acceptor (the optimal delay depends on the length of excitation pulse used, but should be at least ten times longer) .
- the decay of the energy transfer excited acceptor is a function of the decay of donor and the energy transfer efficiency.
- the overall decay is not constant, but is a function of the analyte.
- the decay time of energy transfer emission of acceptor is quite constant and equal to the decay time of donor. The delay and counting times for such measurement is not critical. For assays of higher efficiencies, the decay time decreases upon binding, and steeper response can be obtained keeping short delay time and reasonable short counting time.
- the sample may have a signal decreasing effect.
- the sample may, for example, absorb excitation light, emission light or cause other types of quenchings .
- the interferences can be controlled by various methods, including (1) decay analysis (2) simultaneous photometric monitoring of sample absorption at the wavelengths of excitation and emission, (3) simultaneous measurement of both signals, donor and acceptor, and calculating their correlation and comparing to control with same amounts of donor and acceptor without binding reaction or (4) kinetic measurement during binding following the change of energy transfer or signals.
- the analysis of decay time is an independent parameter not affected by color quenching of neither the excitation nor emission.
- the decay change can be followed both for donor or for acceptor (decrease in decay when energy transfer increases).
- a preferred way to quarantee nondisturbed analysis with all samples is to use suitable combination of all the above mentioned correction methods .
- the energy transfer is registered by a time-resolved fluorometer using a predeterminated instrumental setting avoiding cross talk or donor emission to the channel used for acceptor emission measurement when there is no energy transfer.
- the instrument automatically corrects any attenuation of excitation the sample may cause by following simultaneously the absorbances of the samples diluted into assay mixture and correcting the emission readings according to excitation or emission attenuation by sample absorption.
- the measured acceptor signal can be normalized by recording also the donor emission which can be compared to zero calibrator, the lowering of signal without concomitant increase in acceptor luminescence being recorded and corrected.
- the decay time of either donor or the acceptor can be registered and used as the measuring parameter.
- the decay time of the donor or the acceptor can be utilized in correction of sample interferences .
- a second type of assay where improved energy transfer assays can be applied are assays where dissociations, and not associations, are followed.
- Such assays can be e.g. competitive immunoassays (or other specific binding assay) where antibody-antigen complex is preformed and the addition of analyte causes new equilibrium formations (ligand replacement assays).
- Another group of such assay are the assays of cleaving enzymes, such as peptidases (e.g. HIV peptidases), proteases and other enzymes (e.g. nucleotide hydrolyzing enzymes, helicase, etc.).
- peptidases e.g. HIV peptidases
- proteases e.g. nucleotide hydrolyzing enzymes, helicase, etc.
- the preferred technology is to follow the increased emission of the donor .
- Preferred chelates for assays based on dissociation are to a great extend same as described above for association based assays.
- Terbium is often a better choice, because it can be quenched with a variety of compounds, including metal ions, nitrogen compounds such as azide, nitride (Tanaka et al, J Photochem Photobiol 74; 15, 1993) or radicals (spin labels, such as Doxyl , Proxyl or Tempo and other N-0 compounds containing unpaired electron) (Matko et al, Biochemistry 31; 703, 1992).
- Good Tb chelates suitable for the present invention are mentioned above .
- a preferred acceptor for dissociation measuring assay is a good energy acceptor causing as efficient donor quenching as possible.
- the acceptor can be luminescent, but does not have to be .
- a preferred FRET acceptor has good acceptor properties (R 0 over 5 nm) , but does not have to be highly luminescent.
- the good acceptor can be a respective compound made non-luminescent with heavy atom conjugations (such as erythrosin) or suitable other substituents (see. e.g. Khanna and Ullman, Anal Biochem 108; 156, 1980, Ullman and Khanna, Methods Enzymol 74; 28, 1981).
- steric interference e.g.
- acceptor has to be small, and small molecular quenchers, such as spin labels, are preferred.
- Use of larger acceptors possibly requires indirect approach, i.e. use of small affinity label (small hapten, biotin) and separate step for quenching (addition of acceptor labelled anti-hapten of avidin), which may have to be done after the actual dissociation reaction (end point detection).
- a preferred assay design for e.g. a peptidase is to use peptide substrate labelled at one end with a fluorescent terbium chelate and at the other end with free radical.
- spin quenching and FRET dipole-dipole energy transfer depends on the actual distance between the labels in unhydrolyzed peptide. With small distances (below 2 nm) free radical (spin) is preferred. If the distance of the two probes would be more than 5 nm, a dipole-dipole energy transfer is preferred.
- the energy donor Compound 6 was conjugated to anti- ⁇ hCG antibody (code F19-9C1, Wallac Oy, Turku, Finland) in the following way: anti- ⁇ hCG antibody (5mg/ml) was incubated with a 30-fold molar excess of Compound 6 in 50mM carbonate buffer pH 9.5 over night at +4 °C.
- the labelled antibodies were separated from unreacted Compound 6 by gel filtration (Sepharose 6B with Sephadex G50 overlay, 0.5x70 cm, Pharmacia, Uppsala, Sweden) with Tris (50 mM Tris-HCl, pH 8 containing 0.9% NaCl) as eluetion buffer.
- Tris 50 mM Tris-HCl, pH 8 containing 0.9% NaCl
- the labelled antibody was analyzed and found to contain 4.7 molecules of Compound 6 per antibody. Labelled antibody was kept in Tris buffer, pH 7.4 containing 0.1% bovine serum albumin.
- the energy acceptor TRITC (Molecular Probes Inc, Eugene, OR) was conjugated to anti- ⁇ hCG antibody (code M15294, Wallac Oy) in the following way: anti- ⁇ hCG antibody (5 mg/ml ) was incubated with a 15-fold molar excess of TRITC in 50 mM carbonate buffer pH 9.5 over night at +4 °C.
- the labelled antibodies were separated from unreacted TRITC by gel filtration (Sepharose 6B with Sephadex G50 overlay, 0.5x70 cm, Pharmacia) with Tris (50 mM Tris-HCl, pH 8 containing 0.9% NaCl ) as eluetion buffer.
- the labelled antibody was analyzed and found to contain 1,7 tetramethylrhodamine per antibody. Labelled antibody was kept in Tris buffer, pH 7.4 containing 0.1% bovine serum albumin .
- Two antibodies (Wallac Oy) recognising different epitopes on PSA were labelled with Compound 1 and TRITC, respectively.
- Antibody labelling were carried out as described in example 1 and 2.
- 50 ⁇ l of PSA standard from the commercially available PSA assay kit DELFIA PSA
- 50 ⁇ l of PSA standard was incubated together with 100 ng of Compound 1 (donor) labelled antibody and 100 ng of tetramethylrhodamine labelled antibody (acceptor) in 200 ⁇ l Tris buffer pH 7.4.
- the assay mixtures were incubated for 30 min at room temperature under continous shaking.
- the tetramethylrhodamine fluorescence from the formed complexes (sandwiches) was measured in the Wallac 1420 VICTOR time-resolved fluorometer (Excitation at 340 nm, emission at 572 nm +- 3 nm, delay time 50 ⁇ s, window time 100 ⁇ s, cycle time 1 ms ) .
- the standard curve for the homogenous energy transfer assay is documented in Figure 4.
- This two-site immunoassay was performed as described in Example 3. Instead of using tetramethylrhodamine-labelled antibody (acceptor), biotinylated antibody and tetramethylrhodamine-avidin (acceptor) was used. The tetramethylrhodamine-avidin (Molecular Probes) reacts and forms stable complexes with the biotinylated antibody.
- the anti- ⁇ hCG antibody code M15294
- the tetramethylrhodamine fluorescence from the formed complexes (sandwiches) was measured in the Wallac 1420 VICTOR time-resolved fluorometer (excitation at 340 nm, emission at 572 nm +- 3 nm, delay time 50 ⁇ s, window time 100 ⁇ s, cycle time 1 ms ) .
- the standard curve for the homogenous energy transfer assay is documented in Figure 5.
- Monoclonal anti-progesterone antibody (Wallac Oy) was labelled with Compound 2 according to Example 1.
- Tris buffer was used in the incubations.
- 50 ⁇ l standard or sample was incubated 100 ⁇ l of Compound 2 -labelled antibody (diluted 1/50000) and 100 ⁇ l of progesterone-biotin derivative and tetramethylrodamin-avidin (acceptor).
- the biotinylated progesterone competes with progesterone from the standards or the sample for the binding sites on the labelled anti-progesterone antibody.
- the reaction mixture was incubated for 1 hour at room temperature . After the incubation the fluorescence signal was measured from tetramethylrodamin-avidin bound to the anti-progesterone-antibody-progesterone-biotin complexes with a time-resolved fluorometer (Wallac 1420 VICTOR, excitation at 340 nm, emission at 572 nm, +- 3 nm, delay time 50 ⁇ s, window time 100 ⁇ s, cycle time 1 ms ) .
- the measured signal is inversely related to the progesterone concentration in the sample.
- IL-2 Purified carrier-free IL-2 (R&D Systems, Minneapolis, MN) (1 mg/ml) was incubated with a 10-fold molar excess of Compound 2 in 50mM carbonate buffer pH 9.2 over night at + 4 °C.
- the labelled IL-2 was separated from unreacted chelate by gel filtration (Sephadex G50, 0.7x48 cm, Pharmacia) with Tris as elution buffer.
- the labelled IL-2 was analyzed and found to contain 1.4 molecules of Compound 2 per IL-2 molecule.
- a non-neutralizing antibody directed against the IL-2 receptor was labelled with tetramethylrhodamine isothiocyanate according to Example 2.
- VICTOR excitation at 340 nm, emission at 572 nm +- 3 nm, delay time 50 ⁇ s, window time 100 ⁇ s , cycle time 1 ms ) .
- casein Five milligrams of casein was dissolved in 0.5 mL of 0.1 M sodium carbonate pH 9.2. Fifty icroliters of 5.5 mM fluorescent Compound 6 in water was added to the casein solution and reaction was allowed to proceed overnight at 4 °C. The labelled protein was purified through Sephadex G-50 column using 0.9 % sodium chloride in aqueous solution as an eluent. The labelled casein was analyzed and found to contain one Compound 6 molecule per casein molecule. Two milligrams of Compound 6 -labelled casein in 1 mL was mixed with 100 ⁇ l of 20 mM tetramethylrhodamine isothiocyanate
- TRITC TRITC dissolved in dimethylformamide . After adjusting pH by adding 120 ⁇ l of 1 M sodium carbonate, pH 9.5, reaction mixture was incubated at 4 °C overnight. The labelled protein was purified from unreacted TRITC using Sephadex G-50 column equilibrated and run with 50 mM Tris-HCl pH 8 containing 0.9% NaCl. Using the same protocol as for Compound 6 -labelled casein, unlabelled casein was also labelled with TRITC.
- Casein labelled with Compound 6 and TRITC gave 28 000 cps, casein labelled with Compound 6 and PROXYL 54 000 cps and casein labelled with TRITC 869 cps.
- the abovementioned proteins were measured using excitation at 340 nm, emission at 572 nm +- 3nm (suitable for TRITC), delay time 50 ⁇ s, window time 100 ⁇ s and cycle time 1 ms
- Compound 6 -labelled casein gave 3952 cps, Compound 6- and TRITC-labelled casein 382 000 cps, Compound 6- and PROXYL-labelled casein 4097 cps and TRITC-labelled casein 747 cps.
- Rhodamine-avidin Rh-Av
- PE-Av phycoerythrin-avidin
- the biotin moiety was coupled to the amino terminus of the peptide.
- This peptide is a substrate for Abl protein tyrosine kinase purchased from New England Biolabs .
- the assay was started by incubating 100 nM peptide solution with labelled avidin (concentration 10 ⁇ g/mL). Twenty microliters of peptide-avidin solution was pipetted to clear microtitration wells.
- Rhodamine-avidin 2649 cps 702 000 cps
- oligonucleotides were synthesized using Applied Biosystems DNA/RNA synthesizer:
- oligonucleotides were synthesized and labelled using the chemistry and protocol published earlier (P. Dahlen et al . (1994) Bioconjugate Chem. 5, 268-272).
- X denotes a modified deoxycytidine residue carrying an aliphatic primary amino group suitable for labelling with reagents containing, for example, isothiocyanate group.
- Compound 6 used in this example is fluorescent.
- the labelled probes are able to hybridize with the target oligonucleotide so that upon hybridization the fluorescent Compound 6 and tetramethylrhodamine are separated only by two nucleotides in the target oligonucleotide.
- hybridization solution 0.6 M sodium chloride, 50 mM Tris-HCl pH 8, 0.1 mM EDTA, 0.1% sodium dodecylsulphate .
- the probes were diluted in hybridization solution to give the final concentration of 10 nM each.
- the target oligonucleotide was diluted also in hybridization buffer to give the following concentrations: 1 nM (in the assay 0.1 nM) , 5 nM (in the assay 0.5 nM) and 10 nM (in the assay 1 nM) .
- Hybridization solution alone was used as a target for blank.
- Anti- ⁇ hCG antibody (code M15294) was labelled with Compound 6 as described in Example 1. Fifty microliter of orange fluorescent beads (1.8x10 beads/ml) ( FluoroSpheres , F-8857 from Molecular Probes Inc.) were incubated with 50 ⁇ l Compound 6 -labelled antibody (60 ⁇ g/ l ) in Tris buffer (50 mM Tris-HCl, pH 7.4 containing 0.9% NaCl) for 2 hours. In the reaction mixture Compound 6 -labelled antibody is passively absorbed to the surface of the bead. The background was determined by incubating 50 ⁇ l of beads with 50 ⁇ l buffer and 50 ⁇ l of antibody solution with 50 ⁇ l of buffer.
- the fluorescence from the acceptor molecules in the beads excited by energy transfered from Compound 6 was measured in the Wallac 1240 VICTOR time-resolved fluorometer. Fluorometer setting used were: excitation at 340 nm, emission at 572 nm +- 3nm, delay time 50 ⁇ s , window time 100 ⁇ s, cycle time 1 ms . Results:
- Anti- ⁇ hCG antibody (code M15294) was labelled with Compound 9 as described in Example 1.
- Fifty microliter of crimson fluorescent beads (1.8x10 beads/ml) (FluoroSpheres R ) , F-8855 from Molecular Probes Inc.) were incubated with 50 ⁇ l Compound 9 -labelled antibody (60 ⁇ g/ml ) in Tris buffer (50 mM Tris-HCl, pH 7.4 containing 0.9% NaCl) for 2 hours.
- Tris buffer 50 mM Tris-HCl, pH 7.4 containing 0.9% NaCl
- Compound 9 -labelled antibody is passively absorbed to the surface of the bead.
- the background was determined by incubating 50 ⁇ l of beads with 50 ⁇ l buffer and 50 ⁇ l of antibody solution with 50 ⁇ l of buffer.
- the fluorescence from the acceptor molecules in the beads excited by energy transfered from Compound 9 was measured in the Wallac 1240 VICTOR time-resolved fluorometer. Fluorometer setting used were: excitation at 340 nm, emission at 660 nm +- 1 nm, delay time 100 ⁇ s , window time 100 ⁇ s , cycle time 1 ms . Results:
Abstract
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP97919087A EP0929810A2 (en) | 1996-10-04 | 1997-09-19 | Homogenous luminescence energy transfer assays |
JP10517208A JP2001502055A (en) | 1996-10-04 | 1997-09-19 | Homogeneous luminescence energy transfer assay |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FI963989A FI963989A (en) | 1996-10-04 | 1996-10-04 | Homogeneous methods of determination based on the transmission of luminescence energy |
FI963989 | 1996-10-04 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1998015830A2 true WO1998015830A2 (en) | 1998-04-16 |
WO1998015830A3 WO1998015830A3 (en) | 1998-06-18 |
Family
ID=8546810
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FI1997/000560 WO1998015830A2 (en) | 1996-10-04 | 1997-09-19 | Homogenous luminescence energy transfer assays |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP0929810A2 (en) |
JP (1) | JP2001502055A (en) |
FI (1) | FI963989A (en) |
WO (1) | WO1998015830A2 (en) |
Cited By (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5998146A (en) * | 1998-07-17 | 1999-12-07 | Wallac Oy | Homogeneous luminescence assay method based on energy transfer |
WO2000039335A1 (en) * | 1998-12-24 | 2000-07-06 | Aclara Biosciences, Inc. | Individually addressable solid surfaces for multiplexed operations |
FR2792072A1 (en) * | 1999-04-08 | 2000-10-13 | Cis Bio Int | HOMOGENEOUS METHOD OF DETECTING OR DETERMINING A CHEMICAL OR PHYSICOCHEMICAL INTERACTION |
WO2001040805A1 (en) * | 1999-11-30 | 2001-06-07 | Akzo Nobel N.V. | Steroid compounds for steroid receptor binding assays |
WO2001092882A1 (en) * | 2000-06-02 | 2001-12-06 | Cis Bio International | Method of detecting the presence of a liquid in a mix |
WO2003076939A1 (en) * | 2002-03-08 | 2003-09-18 | Wallac Oy | Dissociative fluorescence enhancement assay |
EP1382965A1 (en) * | 2001-04-23 | 2004-01-21 | Eiken Kagaku Kabushiki Kaisha | Analysis method using reporter (label) intermolecular interaction |
WO2004086049A1 (en) * | 2003-03-28 | 2004-10-07 | Tero Soukka | A homogeneous luminescence energy transfer bioassay |
WO2005033709A1 (en) * | 2003-10-01 | 2005-04-14 | Wallac Oy | Improved homogeneous time-resolved energy transfer assay |
WO2005062048A1 (en) * | 2003-12-01 | 2005-07-07 | Dade Behring Marburg Gmbh | Homogeneous detection method |
WO2006042907A1 (en) * | 2004-10-19 | 2006-04-27 | Wallac Oy | A novel probe and its use in bioaffinity assays |
WO2006042912A1 (en) * | 2004-10-22 | 2006-04-27 | Wallac Oy | Highly sensitive homogeneous assay based on anti-stokes' shift fret measurement |
US7041459B2 (en) | 2001-05-21 | 2006-05-09 | Monogram Biosciences, Inc. | Analyzing phosphorylated proteins |
WO2006125855A1 (en) * | 2005-05-24 | 2006-11-30 | Hidex Oy | Correction method and measurement device for anti-stokes photoluminescence measurement |
US7160735B2 (en) | 2000-04-28 | 2007-01-09 | Monogram Biosciences, Inc. | Tagged microparticle compositions and methods |
WO2007077291A1 (en) | 2005-12-30 | 2007-07-12 | Turun Yliopisto | Method for determination of concentration, charge or unit size of a substance |
US7255999B2 (en) | 2001-05-21 | 2007-08-14 | Monogram Biosciences, Inc. | Methods and compositions for analyzing proteins |
EP1845376A1 (en) * | 2005-01-28 | 2007-10-17 | Shionogi Co., Ltd. | Quantitative measurement method for recombinant protein |
US7358052B2 (en) | 2001-05-26 | 2008-04-15 | Monogram Biosciences, Inc. | Catalytic amplification of multiplexed assay signals |
US7371544B2 (en) | 2000-02-16 | 2008-05-13 | Jussi Nurmi | Homogenous method for the detection of a polynucleotide, with e.g. cleavable lanthanide chelate label |
US7524974B2 (en) | 2002-07-08 | 2009-04-28 | Tetsuo Nagano | Fluorescent probe |
EP2053059A1 (en) | 2007-10-26 | 2009-04-29 | Sanofi-Aventis | Complexes of TRPC domains and SESTD1 domains and methods and uses involving the same |
US7541467B2 (en) | 2004-01-09 | 2009-06-02 | Shigenobu Yano | Fluorescent zinc ion sensor |
US7563582B2 (en) | 2000-11-25 | 2009-07-21 | Sanofi-Aventis Deutschland Gmbh | Process for screening chemical compounds for modulating the interaction of an EVH1 domain and a process for detecting said interaction |
US7569355B2 (en) | 2003-03-28 | 2009-08-04 | Tero Soukka | Homogeneous luminescence energy transfer bioassay |
US7696245B2 (en) | 2003-03-28 | 2010-04-13 | Sekisui Medical Co., Ltd. | Fluorescent probe for zinc |
US7771929B2 (en) | 2000-04-28 | 2010-08-10 | Monogram Biosciences, Inc. | Tag library compounds, compositions, kits and methods of use |
EP2226633A1 (en) | 2009-03-06 | 2010-09-08 | Charité - Universitätsmedizin Berlin | Uses and methods for the identification of a cytoprotective compound involving gp130 or LIFRalpha |
WO2010149780A1 (en) | 2009-06-26 | 2010-12-29 | Sanofi-Aventis | Test system for measuring mest activity as well as methods and uses involving the same |
WO2011054900A1 (en) | 2009-11-06 | 2011-05-12 | Sanofi-Aventis | Methods and uses relating to the identification of compound involved in pain as well as methods of diagnosing algesia |
EP2348129A1 (en) | 2010-01-21 | 2011-07-27 | Sanofi | Methods and uses relating to the identification of compound involved in pain as well as methods of diagnosing algesia |
EP2348130A1 (en) | 2010-01-21 | 2011-07-27 | Sanofi | Methods and uses relating to the identification of compound involved in pain as well as methods of diagnosing algesia |
EP2348128A1 (en) | 2010-01-21 | 2011-07-27 | Sanofi | Methods and uses relating to the identification of compound involved in pain as well as methods of diagnosing algesia |
WO2011113888A1 (en) | 2010-03-18 | 2011-09-22 | Sanofi-Aventis | Methods and uses relating to the identification of compound involved in pain as well as methods of diagnosing algesia |
WO2011113891A1 (en) | 2010-03-18 | 2011-09-22 | Sanofi-Aventis | Methods and uses relating to the identification of compound involved in pain as well as methods of diagnosing algesia |
WO2011113890A1 (en) | 2010-03-18 | 2011-09-22 | Sanofi | Methods and uses relating to the identification of compound involved in pain as well as methods of diagnosing algesia |
EP2390348A1 (en) | 2010-05-25 | 2011-11-30 | Sanofi | Methods and uses relating to the identification of compound involved in pain as well as methods of diagnosing algesia |
EP2390349A1 (en) | 2010-05-25 | 2011-11-30 | Sanofi | Methods and uses relating to the identification of compound involved in pain as well as methods of diagnosing algesia |
CN102353790A (en) * | 2011-06-25 | 2012-02-15 | 南方医科大学 | Homogeneous time-resolved fluorescence analysis method of alpha-fetalprotein |
EP2532755A1 (en) | 2011-06-10 | 2012-12-12 | Sanofi-Aventis | Methods and uses based on Slfn2 expression and relating to the identification and profiling of compounds for use in the treatment or prevention of pain |
USRE44437E1 (en) | 2003-04-01 | 2013-08-13 | Monogram Biosciences, Inc. | Methods for detecting receptor complexes comprising PI3K |
US8652785B2 (en) | 2008-12-04 | 2014-02-18 | Sanofi | Method of screening a modulator of endothelial NO synthase comprising the use of heme binding protein 1 |
CN104181310A (en) * | 2014-07-30 | 2014-12-03 | 美艾利尔(上海)诊断产品有限公司 | Time resolution immunity fluorescence kit for detecting content of beta-hCG as well as preparation method and application thereof |
US9736555B2 (en) | 2013-04-15 | 2017-08-15 | Wallac Oy | Method and a device for cross-talk correction of measured intensities |
US9816926B2 (en) | 2012-06-22 | 2017-11-14 | Macquarie University | Multiplex suspension assay/array using lifetime coding |
WO2021148717A1 (en) | 2020-01-20 | 2021-07-29 | Iptomics Oy | Luminescence hybridisation assay method |
US11112403B2 (en) | 2019-12-04 | 2021-09-07 | Progenity, Inc. | Assessment of preeclampsia using assays for free and dissociated placental growth factor |
US11333672B2 (en) | 2017-09-13 | 2022-05-17 | Progenity, Inc. | Preeclampsia biomarkers and related systems and methods |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2333346C (en) * | 2000-01-31 | 2013-01-22 | The Penn State Research Foundation | Interrogation of changes in the contents of a sealed container |
WO2007125822A1 (en) * | 2006-04-28 | 2007-11-08 | Tokyo Institute Of Technology | Complex for use in the screening of substance |
EP1933151A1 (en) | 2006-12-15 | 2008-06-18 | F. Hoffmann-La Roche Ag | Assays for measuring phosphate modification enzyme activity |
CA2759885A1 (en) * | 2009-04-30 | 2010-11-04 | Etienne Doumazane | Method for detecting compounds modulating dimers of vft domain membrane proteins |
Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1987007955A1 (en) * | 1986-06-17 | 1987-12-30 | Baxter Travenol Laboratories, Inc. | Homogeneous fluoroassay methods employing fluorescent background rejection and water-soluble rare earth metal chelate fluorophores |
US4868103A (en) * | 1986-02-19 | 1989-09-19 | Enzo Biochem, Inc. | Analyte detection by means of energy transfer |
GB2223096A (en) * | 1988-09-06 | 1990-03-28 | Atomic Energy Authority Uk | Detecting a selected species |
US4996143A (en) * | 1985-12-23 | 1991-02-26 | Syngene, Inc. | Fluorescent stokes shift probes for polynucleotide hybridization |
WO1992001224A1 (en) * | 1990-07-13 | 1992-01-23 | Cis Bio International | Method for reducing interference in a fluorescent assay |
US5194300A (en) * | 1987-07-15 | 1993-03-16 | Cheung Sau W | Methods of making fluorescent microspheres |
US5326692A (en) * | 1992-05-13 | 1994-07-05 | Molecular Probes, Inc. | Fluorescent microparticles with controllable enhanced stokes shift |
EP0649020A1 (en) * | 1993-10-13 | 1995-04-19 | Wallac Oy | Luminescent lanthanide chelates with decreased non-radiative energy loss |
WO1996000901A1 (en) * | 1994-06-29 | 1996-01-11 | The Regents Of The University Of California | Luminescent lanthanide chelates and methods of use |
FI96367B (en) * | 1994-10-17 | 1996-02-29 | Erkki Juhani Soini | Biospecific determination method |
US5512493A (en) * | 1990-07-13 | 1996-04-30 | Cis Bio International | Method of amplifying the emission signal of a luminescent compound |
WO1996030540A2 (en) * | 1995-03-20 | 1996-10-03 | The Regents Of The University Of California | Substrates for beta-lactamase and uses thereof |
-
1996
- 1996-10-04 FI FI963989A patent/FI963989A/en unknown
-
1997
- 1997-09-19 EP EP97919087A patent/EP0929810A2/en not_active Withdrawn
- 1997-09-19 JP JP10517208A patent/JP2001502055A/en active Pending
- 1997-09-19 WO PCT/FI1997/000560 patent/WO1998015830A2/en not_active Application Discontinuation
Patent Citations (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4996143A (en) * | 1985-12-23 | 1991-02-26 | Syngene, Inc. | Fluorescent stokes shift probes for polynucleotide hybridization |
US4868103A (en) * | 1986-02-19 | 1989-09-19 | Enzo Biochem, Inc. | Analyte detection by means of energy transfer |
WO1987007955A1 (en) * | 1986-06-17 | 1987-12-30 | Baxter Travenol Laboratories, Inc. | Homogeneous fluoroassay methods employing fluorescent background rejection and water-soluble rare earth metal chelate fluorophores |
US5194300A (en) * | 1987-07-15 | 1993-03-16 | Cheung Sau W | Methods of making fluorescent microspheres |
GB2223096A (en) * | 1988-09-06 | 1990-03-28 | Atomic Energy Authority Uk | Detecting a selected species |
US5512493A (en) * | 1990-07-13 | 1996-04-30 | Cis Bio International | Method of amplifying the emission signal of a luminescent compound |
WO1992001224A1 (en) * | 1990-07-13 | 1992-01-23 | Cis Bio International | Method for reducing interference in a fluorescent assay |
US5326692A (en) * | 1992-05-13 | 1994-07-05 | Molecular Probes, Inc. | Fluorescent microparticles with controllable enhanced stokes shift |
US5326692B1 (en) * | 1992-05-13 | 1996-04-30 | Molecular Probes Inc | Fluorescent microparticles with controllable enhanced stokes shift |
EP0649020A1 (en) * | 1993-10-13 | 1995-04-19 | Wallac Oy | Luminescent lanthanide chelates with decreased non-radiative energy loss |
WO1996000901A1 (en) * | 1994-06-29 | 1996-01-11 | The Regents Of The University Of California | Luminescent lanthanide chelates and methods of use |
FI96367B (en) * | 1994-10-17 | 1996-02-29 | Erkki Juhani Soini | Biospecific determination method |
WO1996030540A2 (en) * | 1995-03-20 | 1996-10-03 | The Regents Of The University Of California | Substrates for beta-lactamase and uses thereof |
Non-Patent Citations (12)
Title |
---|
ANALYTICAL BIOCHEMISTRY, Volume 218, 1994, PENGGUANG WU et al., "Resonance Energy Transfer: Methods and Applications", pp. 1-13. * |
BIOCONJUGATE CHEMISTRY, Volume 6, No. 3, 1995, HEIKKI MIKOLA et al., "Syntheses and Properties of Luminescent Lanthanide Chelate Labels and Labeled Haptenic Antigens for Homogeneous Immunoassays", pages 239-240. * |
CHEMICAL ABSTRACTS, Volume 125, No. 15, 7 Sept. 1996, (Columbus, Ohio, USA), GOTHOT ANDRE et al., "A Strategy for Multiple Immunophenotyping by Image Cytometry: Model Studies Using Latex Microbeads Labeled with Seven Streptavidin-Bound Fluorochromes", page 1, Abstract No. 189844; & CYTOMETRY, 1996, 24(3), 214-225. * |
CLIN. CHEM., Volume 39/9, 1993, GERARD MATHIS, "Rare Earth Cryptates and Homogeneous Fluoroimmunoassays with Human Sera", pages 1953-1959. * |
CLINICAL CHEMISTRY, Volume 41, No. 9, 1995, GERARD MATHIS, "Probing Molecular Interactions with Homogeneous Techniques Based on Rare Earth Cryptates and Fluorescence Energy Transfer", pages 1391-1397. * |
CYTOMETRY, Volume 19, 1995, JANOS MATKO et al., "Luminescence Quenching by Long Range Electron Transfer: A Probe of Protein Clustering and Conformation at the Cell Surface", pages 191-200. * |
DIALOG INFORMATION SERVICE, File 154, Medline, Dialog Accession No. 08019516, Medline Accession No. 95009192, CONDRAU M.A. et al., "Time-Resolved Flow Cytometry for the Measurement of Lanthanide Chelate Fluorescence: I. Concept and Theoretical Evaluation"; & CYTOMETRY, (UNITED STATES), 1 Jul. 1994, 16(3), p187-194. * |
DIALOG INFORMATION SERVICE, File 154, Medline, Dialog Accession No. 08019517, Medline Accession No. 95009193, CONDRAU M.A. et al., "Time-Resolved Flow Cytometry for the Measurement of Lanthanide Chelate Fluorescence: II. Instrument Design and Experimental Results"; & CYTOMETRY, (UNITED STATES), 1 Jul. 1994, 16(3), p195-205. * |
JOURNAL OF ALLOYS AND COMPOUNDS, Volume 249, 1997, ILKKA HEMMILA et al., "Development of Luminescent Lanthanide Chelate Labels for Diagnostic Assays", pages 158-162. * |
JOURNAL OF PHOTOCHEMISTRY AND PHOTOBIOLOGY B: BIOLOGY, Volume 27, 1995, EVA F. GUDGIN DICKSON et al., "New Trends in Photobiology (Invited Reviews), Time-Resolved Detection of Lanthanide Luminescence for Ultrasensitive Bioanalytical Assays", pages 3-19. * |
METH. ENZYNIOL., Volume 246, 1995, PAUL R. SELVIN, "Fluorescence Resonance Energy Transfer", pages 300-335. * |
PROC. NATL. ACAD. SCI. U.S.A., Vol. 91, October 1994, PAUL R. SELVIN et al., "Luminescence Energy Transfer Using a Terbium Chelate: Improvements on Fluorescence Energy Transfer", pages 10024-10028. * |
Cited By (79)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0973036A2 (en) * | 1998-07-17 | 2000-01-19 | Wallac Oy | Homogeneous luminescence assay method based on energy transfer |
EP0973036A3 (en) * | 1998-07-17 | 2000-03-08 | Wallac Oy | Homogeneous luminescence assay method based on energy transfer |
US5998146A (en) * | 1998-07-17 | 1999-12-07 | Wallac Oy | Homogeneous luminescence assay method based on energy transfer |
WO2000039335A1 (en) * | 1998-12-24 | 2000-07-06 | Aclara Biosciences, Inc. | Individually addressable solid surfaces for multiplexed operations |
US6878552B1 (en) * | 1999-04-08 | 2005-04-12 | Cis Bio International French Joint Stock Company | Homogeneous detection and/or determination method for a chemical or physico-chemical interaction |
FR2792072A1 (en) * | 1999-04-08 | 2000-10-13 | Cis Bio Int | HOMOGENEOUS METHOD OF DETECTING OR DETERMINING A CHEMICAL OR PHYSICOCHEMICAL INTERACTION |
WO2000062072A1 (en) * | 1999-04-08 | 2000-10-19 | Cis Bio International | Homogeneous detection and/or determination method for a chemical or physico-chemical interaction |
WO2001040805A1 (en) * | 1999-11-30 | 2001-06-07 | Akzo Nobel N.V. | Steroid compounds for steroid receptor binding assays |
US7371544B2 (en) | 2000-02-16 | 2008-05-13 | Jussi Nurmi | Homogenous method for the detection of a polynucleotide, with e.g. cleavable lanthanide chelate label |
US7771929B2 (en) | 2000-04-28 | 2010-08-10 | Monogram Biosciences, Inc. | Tag library compounds, compositions, kits and methods of use |
US7160735B2 (en) | 2000-04-28 | 2007-01-09 | Monogram Biosciences, Inc. | Tagged microparticle compositions and methods |
US6952259B2 (en) | 2000-06-02 | 2005-10-04 | Cis Bio International | Method of detecting the presence of a liquid in a mix |
FR2809817A1 (en) * | 2000-06-02 | 2001-12-07 | Cis Bio Int | METHOD FOR DETECTING THE PRESENCE OF A LIQUID IN A MIXTURE |
WO2001092882A1 (en) * | 2000-06-02 | 2001-12-06 | Cis Bio International | Method of detecting the presence of a liquid in a mix |
US7563582B2 (en) | 2000-11-25 | 2009-07-21 | Sanofi-Aventis Deutschland Gmbh | Process for screening chemical compounds for modulating the interaction of an EVH1 domain and a process for detecting said interaction |
EP1405079B1 (en) * | 2000-11-25 | 2012-05-30 | Sanofi-Aventis Deutschland GmbH | Modulation of the interaction between evh1 domains |
EP1382965A1 (en) * | 2001-04-23 | 2004-01-21 | Eiken Kagaku Kabushiki Kaisha | Analysis method using reporter (label) intermolecular interaction |
US7595202B2 (en) | 2001-04-23 | 2009-09-29 | Teruyuki Nagamune | Analysis method using reporter (label) intermolecular interaction |
EP1382965A4 (en) * | 2001-04-23 | 2004-09-29 | Eiken Chemical | Analysis method using reporter (label) intermolecular interaction |
US7255999B2 (en) | 2001-05-21 | 2007-08-14 | Monogram Biosciences, Inc. | Methods and compositions for analyzing proteins |
US7041459B2 (en) | 2001-05-21 | 2006-05-09 | Monogram Biosciences, Inc. | Analyzing phosphorylated proteins |
US9939447B2 (en) | 2001-05-21 | 2018-04-10 | Monogram Biosciences, Inc. | Methods and compositions for analyzing proteins |
US7358052B2 (en) | 2001-05-26 | 2008-04-15 | Monogram Biosciences, Inc. | Catalytic amplification of multiplexed assay signals |
US7211440B2 (en) | 2002-03-08 | 2007-05-01 | Wallac Oy | Dissociative fluorescence enhancement assay |
CN100350250C (en) * | 2002-03-08 | 2007-11-21 | 沃拉克有限公司 | Dissociative fluorescence enhancement assay |
WO2003076939A1 (en) * | 2002-03-08 | 2003-09-18 | Wallac Oy | Dissociative fluorescence enhancement assay |
US7381567B2 (en) | 2002-03-08 | 2008-06-03 | Wallac Oy | Dissociative fluorescence enhancement assay |
US7524974B2 (en) | 2002-07-08 | 2009-04-28 | Tetsuo Nagano | Fluorescent probe |
WO2004086049A1 (en) * | 2003-03-28 | 2004-10-07 | Tero Soukka | A homogeneous luminescence energy transfer bioassay |
US7569355B2 (en) | 2003-03-28 | 2009-08-04 | Tero Soukka | Homogeneous luminescence energy transfer bioassay |
US7696245B2 (en) | 2003-03-28 | 2010-04-13 | Sekisui Medical Co., Ltd. | Fluorescent probe for zinc |
USRE44437E1 (en) | 2003-04-01 | 2013-08-13 | Monogram Biosciences, Inc. | Methods for detecting receptor complexes comprising PI3K |
WO2005033709A1 (en) * | 2003-10-01 | 2005-04-14 | Wallac Oy | Improved homogeneous time-resolved energy transfer assay |
US7846658B2 (en) | 2003-10-01 | 2010-12-07 | Wallac Oy | Homogeneous time-resolved energy transfer assay |
US8628933B2 (en) | 2003-12-01 | 2014-01-14 | Siemens Healthcare Diagnostics Products Gmbh | Homogeneous detection method |
US8399209B2 (en) | 2003-12-01 | 2013-03-19 | Siemens Healthcare Diagnostics Products Gmbh | Homogeneous detection method |
WO2005062048A1 (en) * | 2003-12-01 | 2005-07-07 | Dade Behring Marburg Gmbh | Homogeneous detection method |
US7541467B2 (en) | 2004-01-09 | 2009-06-02 | Shigenobu Yano | Fluorescent zinc ion sensor |
WO2006042907A1 (en) * | 2004-10-19 | 2006-04-27 | Wallac Oy | A novel probe and its use in bioaffinity assays |
GB2433993A (en) * | 2004-10-19 | 2007-07-11 | Wallac Oy | A novel probe and its use in bioaffinity assays |
GB2433993B (en) * | 2004-10-19 | 2010-04-28 | Wallac Oy | Single molecule TR-FRET probe |
WO2006042912A1 (en) * | 2004-10-22 | 2006-04-27 | Wallac Oy | Highly sensitive homogeneous assay based on anti-stokes' shift fret measurement |
GB2433994A (en) * | 2004-10-22 | 2007-07-11 | Wallac Oy | Highly sensitive homogeneous assay based on anti-stokes' shift fret measurement |
EP1845376A1 (en) * | 2005-01-28 | 2007-10-17 | Shionogi Co., Ltd. | Quantitative measurement method for recombinant protein |
EP1845376A4 (en) * | 2005-01-28 | 2008-07-09 | Shionogi & Co | Quantitative measurement method for recombinant protein |
US7826052B2 (en) | 2005-05-24 | 2010-11-02 | Hidex Oy | Correction method and measurement device for anti-stokes photoluminescence measurement |
WO2006125855A1 (en) * | 2005-05-24 | 2006-11-30 | Hidex Oy | Correction method and measurement device for anti-stokes photoluminescence measurement |
WO2007077291A1 (en) | 2005-12-30 | 2007-07-12 | Turun Yliopisto | Method for determination of concentration, charge or unit size of a substance |
EP2053059A1 (en) | 2007-10-26 | 2009-04-29 | Sanofi-Aventis | Complexes of TRPC domains and SESTD1 domains and methods and uses involving the same |
US8652785B2 (en) | 2008-12-04 | 2014-02-18 | Sanofi | Method of screening a modulator of endothelial NO synthase comprising the use of heme binding protein 1 |
EP2226633A1 (en) | 2009-03-06 | 2010-09-08 | Charité - Universitätsmedizin Berlin | Uses and methods for the identification of a cytoprotective compound involving gp130 or LIFRalpha |
WO2010099979A2 (en) | 2009-03-06 | 2010-09-10 | Charité - Universitätsmedizin Berlin Gliedkörperschaft Der Freien Universität Berlin Und Der Humboldt-Universität Berlin | Uses and methods for the identification of a cytoprotective compound involving gp130 or lifralpha |
EP2267152A1 (en) | 2009-06-26 | 2010-12-29 | Sanofi-Aventis | Test system for measuring MEST activity as well as methods and uses involving the same |
WO2010149780A1 (en) | 2009-06-26 | 2010-12-29 | Sanofi-Aventis | Test system for measuring mest activity as well as methods and uses involving the same |
WO2011054900A1 (en) | 2009-11-06 | 2011-05-12 | Sanofi-Aventis | Methods and uses relating to the identification of compound involved in pain as well as methods of diagnosing algesia |
EP2348128A1 (en) | 2010-01-21 | 2011-07-27 | Sanofi | Methods and uses relating to the identification of compound involved in pain as well as methods of diagnosing algesia |
EP2348130A1 (en) | 2010-01-21 | 2011-07-27 | Sanofi | Methods and uses relating to the identification of compound involved in pain as well as methods of diagnosing algesia |
EP2348129A1 (en) | 2010-01-21 | 2011-07-27 | Sanofi | Methods and uses relating to the identification of compound involved in pain as well as methods of diagnosing algesia |
WO2011089192A1 (en) | 2010-01-21 | 2011-07-28 | Sanofi-Aventis | Methods and uses relating to the identification of compound involved in pain as well as methods of diagnosing algesia |
WO2012052189A1 (en) | 2010-01-21 | 2012-04-26 | Sanofi-Aventis | Methods and uses relating to the identification of compound involved in pain as well as methods of diagnosing algesia |
WO2011089194A1 (en) | 2010-01-21 | 2011-07-28 | Sanofi-Aventis | Methods and uses relating to the identification of compound involved in pain as well as methods of diagnosing algesia |
WO2011113888A1 (en) | 2010-03-18 | 2011-09-22 | Sanofi-Aventis | Methods and uses relating to the identification of compound involved in pain as well as methods of diagnosing algesia |
US8673823B2 (en) | 2010-03-18 | 2014-03-18 | Sanofi | Methods and uses relating to the identification of compound involved in pain as well as methods of diagnosing algesia |
WO2011113890A1 (en) | 2010-03-18 | 2011-09-22 | Sanofi | Methods and uses relating to the identification of compound involved in pain as well as methods of diagnosing algesia |
WO2011113891A1 (en) | 2010-03-18 | 2011-09-22 | Sanofi-Aventis | Methods and uses relating to the identification of compound involved in pain as well as methods of diagnosing algesia |
WO2011147850A1 (en) | 2010-05-25 | 2011-12-01 | Sanofi-Aventis | Methods and uses relating to the identification of compound involved in pain as well as methods of diagnosing algesia |
WO2011147851A1 (en) | 2010-05-25 | 2011-12-01 | Sanofi-Aventis | Methods and uses relating to the identification of compound involved in pain as well as methods of diagnosing algesia |
EP2390349A1 (en) | 2010-05-25 | 2011-11-30 | Sanofi | Methods and uses relating to the identification of compound involved in pain as well as methods of diagnosing algesia |
EP2390348A1 (en) | 2010-05-25 | 2011-11-30 | Sanofi | Methods and uses relating to the identification of compound involved in pain as well as methods of diagnosing algesia |
WO2012168452A1 (en) | 2011-06-10 | 2012-12-13 | Sanofi | Methods and uses based on slfn2 expression and relating to the identification and profiling of compounds for use in the treatment or prevention of pain |
EP2532755A1 (en) | 2011-06-10 | 2012-12-12 | Sanofi-Aventis | Methods and uses based on Slfn2 expression and relating to the identification and profiling of compounds for use in the treatment or prevention of pain |
CN102353790A (en) * | 2011-06-25 | 2012-02-15 | 南方医科大学 | Homogeneous time-resolved fluorescence analysis method of alpha-fetalprotein |
US9816926B2 (en) | 2012-06-22 | 2017-11-14 | Macquarie University | Multiplex suspension assay/array using lifetime coding |
US9736555B2 (en) | 2013-04-15 | 2017-08-15 | Wallac Oy | Method and a device for cross-talk correction of measured intensities |
CN104181310A (en) * | 2014-07-30 | 2014-12-03 | 美艾利尔(上海)诊断产品有限公司 | Time resolution immunity fluorescence kit for detecting content of beta-hCG as well as preparation method and application thereof |
US11333672B2 (en) | 2017-09-13 | 2022-05-17 | Progenity, Inc. | Preeclampsia biomarkers and related systems and methods |
US11112403B2 (en) | 2019-12-04 | 2021-09-07 | Progenity, Inc. | Assessment of preeclampsia using assays for free and dissociated placental growth factor |
US11327071B2 (en) | 2019-12-04 | 2022-05-10 | Progenity, Inc. | Assessment of preeclampsia using assays for free and dissociated placental growth factor |
WO2021148717A1 (en) | 2020-01-20 | 2021-07-29 | Iptomics Oy | Luminescence hybridisation assay method |
Also Published As
Publication number | Publication date |
---|---|
FI963989A (en) | 1998-04-05 |
WO1998015830A3 (en) | 1998-06-18 |
EP0929810A2 (en) | 1999-07-21 |
JP2001502055A (en) | 2001-02-13 |
FI963989A0 (en) | 1996-10-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1998015830A2 (en) | Homogenous luminescence energy transfer assays | |
EP0973036B1 (en) | Homogeneous luminescence assay method based on energy transfer | |
Yuan et al. | Lanthanide complex-based fluorescence label for time-resolved fluorescence bioassay | |
Hemmilá et al. | Time-resolution in fluorometry technologies, labels, and applications in bioanalytical assays | |
AU688928B2 (en) | Luminescent lanthanide chelates and methods of use | |
US7826052B2 (en) | Correction method and measurement device for anti-stokes photoluminescence measurement | |
US5656207A (en) | Detecting or quantifying multiple analytes using labelling techniques | |
JP5841525B2 (en) | Fluorescence assay | |
US6908769B2 (en) | Dye pair for fluorescence resonance energy transfer (FRET) measurements | |
JP2012521208A5 (en) | ||
CA2261758A1 (en) | Assays employing electrochemiluminescent labels and electrochemiluminescence quenchers | |
WO1991000511A1 (en) | Detecting or quantifying multiple analytes using labelling techniques | |
EP2118658B1 (en) | Improved homogeneous luminescence bioassay | |
Deshpande | Principles and applications of luminescence spectroscopy | |
EP1957670B1 (en) | Homogeneous luminescence bioassay | |
O'Riordan et al. | Monofunctional derivatives of coproporphyrins for phosphorescent labeling of proteins and binding assays | |
Kolb et al. | Homogeneous, time-resolved fluorescence method for drug discovery | |
Kokko et al. | Particulate and soluble Eu (III)-chelates as donor labels in homogeneous fluorescence resonance energy transfer based immunoassay | |
US20060115842A1 (en) | Highly sensitive homogeneous assay based on anti-Stokes' shift FRET measurement | |
Selvin | Lanthanide-labeled DNA | |
Wolfbeis et al. | Advanced luminescent labels, probes and beads and their application to luminescence bioassay and imaging | |
US6951760B2 (en) | Diagnostic neodymium(III), ytterbium(III), or erbium(III) ion-ligand complexes | |
Diamandis et al. | Fluorescence immunoassay: and DNA Hybridization Assays | |
Kokko | Lanthanide Chelates as donors in fluorescence resonance energy transfer: exciting prospects for bioaffinity assay detection | |
Kolb¹ et al. | Homogeneous, Time-Resolved |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
AK | Designated states |
Kind code of ref document: A3 Designated state(s): JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1997919087 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 1998 517208 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09180854 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 1997919087 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1997919087 Country of ref document: EP |